CEO, InClinica, United States
Lecture: The global clinical trial crisis
The CRO market is expected to reach more than $45 billion by 2022. The CRO industry is growing at a rapid rate, affecting the pharma industry, biotech companies and academic arenas.
Clinical trials are being conducted on virtually every clinical condition, but some conditions are receiving overwhelmingly more attention. For example, there are less than 9,000 medical device clinical trials currently recruiting, according to ClinicalTrials.Gov. Compare that to oncology, which currently has more than 15,000 recruiting studies.
This lecture will delve into the general industry perspective on clinical trials, with a focus on medical device trials, as well as the key approaches that companies must have in order to succeed in their clinical trials and the importance of labeling.
Lecture: Labeling in medical devices
James Nolan, CEO of InClinica, has more than 25 years of experience in the life sciences industry, representing numerous major pharmaceutical companies. He specializes in creating high-quality research programs and managing an executive team, and his experience extends to areas including R&D evaluation and implementation, product development and marketing, new product launches and recruiting top scientific talent. Mr. Nolan’s mission is to explore and identify business opportunities and novel technologies to establish new life science companies, both domestically and globally.
Mr. Nolan began his pharmaceutical career at Merrill Dow Pharmaceuticals, a division of Dow Chemical. Following his time at Dow, Mr. Nolan served as the Director of Product Planning and Marketing, North America for Anequest focusing on anesthesia and related products, and then was responsible for global marketing and new product and program development at Wyeth-Ayerst International.
He is a graduate of Villanova University and completed the Executive Progam in Marketing Management at the University of Michigan.